150 related articles for article (PubMed ID: 7016320)
1. Phase II clinical trial of VP-16-213 in ovarian cancer.
Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
[No Abstract] [Full Text] [Related]
2. Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Issell BF; Einhorn LH; Comis RL; Lawson RD; Baker LH; Harvey HA; Lanzotti VA; Wampler GL; Daniels JR; Anderson PN
Cancer Treat Rep; 1985 Jan; 69(1):127-8. PubMed ID: 2981617
[No Abstract] [Full Text] [Related]
3. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Edmonson JH; Decker DG; Malkasian GD; Webb MJ; Jorgensen EO
Gynecol Oncol; 1978 Feb; 6(1):7-9. PubMed ID: 620951
[No Abstract] [Full Text] [Related]
4. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].
Suzuki K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024
[TBL] [Abstract][Full Text] [Related]
5. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
Slayton RE; Creasman WT; Petty W; Bundy B; Blessing JA
Cancer Treat Rep; 1979; 63(11-12):2089-92. PubMed ID: 526942
[No Abstract] [Full Text] [Related]
7. Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Hillcoat BL; Campbell JJ; Pepperell R; Quinn MA; Bishop JF; Day A
Gynecol Oncol; 1985 Oct; 22(2):162-6. PubMed ID: 4054715
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
Gockerman JP; Bartolucci AA; Nelson MO; Silberman H; Velez-Garcia E; Stein R
Cancer Treat Rep; 1986 Jun; 70(6):801-2. PubMed ID: 3524829
[No Abstract] [Full Text] [Related]
9. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of a new form of an oral administration of VP-16-213.
Lau ME; Hansen HH; Nissen NI; Pedersen H
Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801
[TBL] [Abstract][Full Text] [Related]
11. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
Muss H; Bundy BN; DiSaia PJ; Twiggs LB
Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
[No Abstract] [Full Text] [Related]
12. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
13. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
14. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
15. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
16. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Kimura K; Yamada K; Yoshida T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of diaziquone in advanced ovarian carcinoma. European Organization for Research on Treatment of Cancer Early Clinical Trials Group.
Lund B; Bramwell V; Renard J; Hansen HH; Dombernowsky P
Cancer Treat Rep; 1985 Mar; 69(3):339-40. PubMed ID: 3872170
[No Abstract] [Full Text] [Related]
18. Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
Kelsen DP; Magill GB; Cheng E; Dukeman M; Sordillo P; Heelan R; Yagoda A
Cancer Treat Rep; 1983 May; 67(5):509-10. PubMed ID: 6850667
[No Abstract] [Full Text] [Related]
19. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
[No Abstract] [Full Text] [Related]
20. Phase II trial of etoposide in advanced prostate cancer.
Trump DL; Loprinzi CL
Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
